What changed for Breast Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Breast Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 854 to 880 (+26)
- Late-stage (Phase 3) trials 97 to 98 (+1)
- Trials on record 5,278 to 5,478 (+200)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Breast Cancer in July 2026. Voxsanity tracks 24 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 186 trials tracked for Breast Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04216472 · results posted 7 July 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two medicines — alpelisib and nab-paclitaxel — given to breast cancer patients before surgery (this is called "neoadjuvant" treatment, meaning treatment given before an operation). The trial was measuring something called a "pathological complete response," which means no cancer can be found in the tissue removed during surgery. A total of 6 people were enrolled, 5 completed the study, and 1 did not finish. The reported data shows that out of the 5 participants who completed the study, 1 person had...
-
NCT03289364 · results posted 28 April 2026
According to the results reported on ClinicalTrials.gov, this trial looked at whether Penguin Cold Caps — devices worn during chemotherapy to cool the scalp — could reduce or prevent chemotherapy-related hair loss. Twelve people took part, ten completed the study, and two did not finish. Participants' hair loss was assessed 30 days after completing chemotherapy using a grading scale called the Dean's alopecia scale, which rates hair loss from Grade 0 (no hair loss) through to Grade 4 (more than 75% hair loss). The main goal was to find out how many participants lost less than 50% of their hair...
-
NCT05654623 · results posted 3 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05654623) compared two treatments — vepdegestrant (also called ARV-471) and fulvestrant — in people with a type of breast cancer. A total of 313 people were assigned to the vepdegestrant group and 311 to the fulvestrant group, making 624 participants in all. The trial's main focus was on something called "progression-free survival" (PFS) — that is, how long participants went without their cancer visibly growing or spreading, or dying, based on independent scans and imaging reviews. This was measured for all participants co...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03879577 · results posted 21 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 53 people, all of whom received a combination of two medicines — Taxotere (a chemotherapy) and Trastuzumab (a targeted therapy) — before surgery for breast cancer. This type of treatment given before surgery is called "neoadjuvant" therapy. The main thing the trial was measuring was how many participants showed a "complete pathologic response," meaning that when doctors examined the removed tissue under a microscope after surgery, no invasive cancer cells could be found in the breast or nearby lymph nodes. Forty-seven...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04534010 · results posted 17 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04534010) enrolled 6 participants, all of whom were patients receiving NAC (nipple-areola complex) grafts. The trial was measuring how well these grafts healed over time, specifically looking at whether the graft tissue reached what the researchers defined as "complete healing" — meaning more than 99% of the graft surface had re-formed a skin layer. Of the 6 people who started the trial, 4 completed it, and 2 did not complete it (the reasons were not detailed in the reported data). The reported data shows that the primary...
-
NCT05757427 · results posted 26 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05757427) involved 73 people who received a breast scan using a device called Wavelia MWBI (Microwave Breast Imaging). Of those, 62 people completed the trial and 11 did not finish. The trial was measuring how well the Wavelia MWBI scan could detect breast lesions (abnormal areas in the breast, which can be either cancerous or non-cancerous), and how accurately it could estimate their size compared to ultrasound measurements. The reported data shows that, for the primary goal of detecting breast lesions, the device correc...
-
NCT04305496 · results posted 27 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04305496) enrolled a total of 842 people across two groups — a Global Cohort (708 participants) and a China Cohort (134 participants). In each cohort, participants were randomly assigned to receive either capivasertib combined with fulvestrant, or a placebo combined with fulvestrant. The trial was primarily measuring **progression-free survival** — that is, how long participants went before their cancer showed signs of growing or spreading (called "progression"), or before they died from any cause. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06133348 · results posted 14 October 2025
According to the results reported on ClinicalTrials.gov, this trial tested a programme called PRISM with 43 participants. The main question the trial was trying to answer was whether the programme was *feasible* — meaning, could it realistically be run and completed by enough people? The researchers set a target of at least 70% of participants finishing all sessions and completing surveys before and after the programme. Of the 43 people who started, 33 completed the programme and 10 did not. The reported data shows that the 33 completers met the pre-set feasibility target (roughly 77%, above...
-
NCT04958785 · results posted 3 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04958785) enrolled 92 participants across five groups. It tested two different drug combinations involving magrolimab — one paired with a chemotherapy drug called nab-paclitaxel or paclitaxel, and another paired with a drug called sacituzumab govitecan — in people with a type of breast cancer. The trial had an initial safety check phase (called a "safety run-in") followed by a larger Phase 2 portion. Notably, zero participants in any group were recorded as having "completed" the study, meaning all participants exited befor...
-
NCT01703754 · results posted 28 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01703754) tested a combination of an investigational gene therapy called Ad-RTS-hIL-12 together with a companion drug called Veledimex, given at three different daily doses (80 mg, 100 mg, or 140 mg), in people with a type of cancer. A total of 12 participants started the trial across the three dose groups — 7 in the 140 mg group, 4 in the 100 mg group, and 1 in the 80 mg group. The trial was primarily measuring how many participants experienced unwanted medical events (called adverse events) after starting treatment, and...
-
NCT04862585 · results posted 20 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04862585) enrolled 98 people in total — 50 in one group who received the chemotherapy drug paclitaxel along with pre-medications (drugs given beforehand to try to prevent allergic-type reactions), and 48 in a second group who received paclitaxel without those pre-medications. The trial was primarily measuring how many people in each group had a moderate-to-severe infusion reaction — that is, an allergic-type response during the drip — serious enough to need emergency rescue medicines injected to treat it, looking at the fi...
-
NCT04740918 · results posted 8 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04740918) enrolled 96 people in total — 50 in one group who received a medicine called trastuzumab emtansine plus a placebo (a dummy treatment), and 46 in a second group who received trastuzumab emtansine plus a second medicine called atezolizumab. The trial was measuring two main things: how long participants went without their cancer growing or spreading (called progression-free survival, or PFS), and how long participants lived overall (overall survival, or OS). It also looked at a number of secondary measures, includin...
-
NCT04256512 · results posted 28 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 94 participants, all of whom were assigned to use Elasto Gel Therapy Mittens and Foot Wraps — a type of cooling glove and foot wrap worn during chemotherapy. The trial was measuring how many participants developed chemotherapy-induced peripheral neuropathy (CIPN), which is a condition involving tingling, numbness, or pain in the hands and feet that can occur as a side effect of some chemotherapy treatments. Ninety-three of the 94 participants completed the study, with one person not completing it. The reported data s...
-
NCT04915755 · results posted 16 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04915755) enrolled 40 people in total — 18 received niraparib and 22 received a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring safety-related observations, including how many participants experienced adverse events (unwanted medical occurrences during the study), serious adverse events, events leading to death, and events that caused changes to their dose or led them to stop treatment altogether. The trial also tracked participants' general functioning levels and changes in blood t...
-
NCT04975308 · results posted 11 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04975308) enrolled 874 participants across three groups: 331 people received imlunestrant alone (Arm A), 330 received a hormone therapy chosen by their doctor (Arm B), and 213 received imlunestrant combined with another drug called abemaciclib (Arm C). The trial was primarily measuring "progression-free survival" — that is, how long, in months, participants went without their cancer growing or spreading, or without dying. A key sub-group analysis also looked separately at participants whose tumours had a specific gene chan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04739761 · results posted 16 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04739761) enrolled 504 people in total — 241 in Cohort 1 (participants who did not have brain metastases, meaning cancer that had spread to the brain, at the start of the trial) and 263 in Cohort 2 (participants who did have brain metastases at the start). All participants received a medicine called trastuzumab deruxtecan (T-DXd). The trial was measuring two main things: how many people in Cohort 1 had their tumours shrink or disappear, and how many people in Cohort 2 were still alive and free of disease worsening after 12...
-
NCT03183050 · results posted 30 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03183050) involved 88 participants who all received something called a QPL (a question prompt list — a tool designed to help patients ask questions during medical consultations). The trial was measuring participants' knowledge related to genetic testing and treatment options, for example in the context of breast cancer. Of the 88 people who started, 65 completed the study, and 23 did not finish. The reported data shows that knowledge was measured using a combined score covering two areas: understanding of genetic testing...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04494425 · results posted 2 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04494425) enrolled 866 people in total — 436 assigned to a treatment called T-DXd and 430 assigned to standard chemotherapy. Participants had a type of breast cancer described as HER2-low (meaning the cancer cells carry a small amount of a particular protein called HER2). The trial's main goal was to measure how long participants went without their cancer growing or spreading — a period called "progression-free survival" — and it also tracked how long participants lived overall, as well as how many showed a measurable shri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00971087 · results posted 26 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 3,521 people undergoing breast cancer screening, and all 3,521 completed the study. The trial was comparing two types of mammography imaging: a combined 3D-plus-synthesised-2D approach (referred to as "3D + s2D") against standard 2D digital mammography ("2D FFDM"). The main thing being measured was how well each imaging type performed at distinguishing between scans that did and did not show cancer, using a standard scoring method called the "area under the curve" (AUC) — a proportion scored from 0 to 1, where a highe...
-
NCT03222856 · results posted 19 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 44 people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative metastatic breast cancer) who had already received certain prior chemotherapy treatments. All 44 participants received a combination of two medicines — pembrolizumab and eribulin. Of the 44 who started, 37 completed the trial and 7 did not. The trial was primarily measuring something called the "clinical benefit rate" — that is, how many participants either saw their tumours shrink or had their disease remain stable for...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02386371 · results posted 6 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02386371) enrolled 66 people who had experienced a local return of breast cancer after earlier breast-conserving treatment. All participants received a second round of breast-conserving surgery combined with intraoperative radiotherapy — that is, a single dose of radiation delivered directly to the surgical site during the operation. The trial's main goal was to assess how well patients tolerated this approach, specifically by looking at a tissue-hardening side effect called fibrosis at 12 months after treatment. Fifty-thr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03482557 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 132 participants, all of whom completed the study. The trial was comparing three different breast imaging methods — contrast-enhanced spectral mammography (CESM, a type of mammogram using a contrast dye), standard breast MRI (a magnetic resonance scan), a shorter "abbreviated" version of breast MRI, and conventional 2D mammography — to see how well each method could identify breast cancer. Radiologists reviewed the scans and rated the likelihood of cancer in each case. The reported data shows the results using a meas...
-
NCT03673306 · results posted 13 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 4,732 women who had previously been diagnosed with breast cancer. They were divided into two groups: 659 women who became pregnant after their breast cancer diagnosis (the "Pregnant Cohort") and 4,073 women who did not become pregnant after their diagnosis (the "Non-pregnant Cohort"). The trial was measuring two main things: how many women became pregnant after their breast cancer diagnosis, and how long women in each group went without their cancer returning or worsening (called "disease-free survival"). It also trac...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03487666 · results posted 3 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03487666) enrolled 45 people in total — 15 in each of three groups. One group received a drug called nivolumab (Arm A), one received a drug called capecitabine (Arm B), and one received both drugs together (Arm C). The trial was primarily measuring changes in something called the "Peripheral Immunoscore" (PIS) — a scoring system that tracks certain immune cells in the blood to give an overall picture of immune activity. A positive change in this score was defined as suggesting increased immune activity, and a negative chan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03901339 · results posted 21 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03901339) enrolled 272 people in the sacituzumab govitecan group and 271 people in the comparator group, which received a treatment chosen by their doctor (called "Treatment of Physician's Choice"). The trial was measuring how long participants went without their cancer growing or spreading (called progression-free survival), how long they lived overall, and a number of other related measures such as how many people's cancer shrank, how long that shrinkage lasted, and how many people experienced any meaningful benefit from...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04191499 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04191499) enrolled 325 people in total — 161 in one group and 164 in the other. Participants were randomly assigned to receive either a combination of three medicines (inavolisib, palbociclib, and fulvestrant, referred to here as Inavo+Palbo+Fulv) or a similar combination where inavolisib was replaced by a placebo — an inactive dummy treatment (Pbo+Palbo+Fulv). The trial's main goal was to measure "progression-free survival" (PFS), which is the length of time from when a participant joined the trial until their cancer show...
-
NCT02999477 · results posted 20 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02999477) involved 32 people in total, split into two groups of 16 — one group received nab-paclitaxel (a chemotherapy medicine) and the other received pembrolizumab (an immunotherapy medicine). The trial was looking at what happens before surgery for breast cancer ("neoadjuvant" treatment). It primarily measured changes in a protein marker called PD-L1, which is found on tumour cells and can be detected in tissue samples. A number of secondary measurements were also taken, including changes in immune cells within the tumo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03280303 · results posted 20 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,250 people who were receiving a combination of palbociclib and endocrine (hormone-based) therapy for breast cancer. Only 54 participants were recorded as having completed the study, while 1,196 did not complete it — though in an observational study like this one, not completing does not necessarily mean dropping out due to a problem. The trial was measuring things like how tumours responded to treatment, how long it was before the disease progressed, and how long participants lived overall. It also looked at a measu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00626106 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial involved 156 people with breast cancer — 106 in one group and 50 in another. The main thing the trial was measuring was **progression-free survival**: how long participants went before their disease got worse, they felt significantly worse, or they died. One group received a drug called AMG 479 (also known as ganitumab) given by drip into a vein, combined with a hormone-based cancer treatment. The other group received a dummy (placebo) drip combined with the same hormone-based treatment. The reported data shows that for the p...
-
NCT03284723 · results posted 3 September 2024
According to the results reported on ClinicalTrials.gov, this trial investigated an experimental drug called PF-06804103 in people with breast cancer. A total of 95 participants took part, spread across 12 groups that received different doses of the drug (ranging from 0.15 mg/kg to 5.0 mg/kg of body weight). Some groups received the drug on its own, while one small group received it in combination with other medicines. The trial was primarily measuring how the body tolerated the drug at different dose levels — specifically looking for serious side effects early in treatment, unusual changes in...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 186 reported results for Breast Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, breast cancer receives a very large amount of public research funding from the United States, and that level has remained broadly steady over time. This suggests that breast cancer is a well-established research priority, with sustained institutional commitment to understanding and addressing the disease. For patients, this kind of consistent investment generally mea...
See the full Breast Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.